Selective toxicity of anticancer drugs: Presidential Address

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Selective toxicity in chemotherapy has been successful for infectious diseases and specific young patient tumor types using pharmacokinetic data.
• Past attempts to improve antitumor drug efficacy in diverse human tumors via kinetic observations have yielded disappointing results.
• Tumor cell heterogeneity is a key barrier to understanding the relationship between cellular/drug kinetics and selective toxicity.

Observation:

• Tumor xenografts, flow cytometry, and tumor markers offer novel tools to isolate and study distinct tumor cell subpopulations.
• These techniques allow for detailed characterization of cellular and drug kinetics within specific tumor cell populations.
• This data can be correlated with in vivo human pharmacokinetic values.

Findings:

• Characterizing kinetic properties of isolated tumor cell subpopulations is now feasible.
• Correlation of subpopulation kinetics with human in vivo data can be achieved.
• This approach addresses the limitations imposed by tumor heterogeneity.

Implications:

• Enables a deeper understanding of how cellular and drug kinetics influence selective toxicity in human cancers.
• Paves the way for developing optimized, individualized drug schedules for cancer patients.
• Offers a promising strategy to enhance the efficacy and reduce side effects of cancer chemotherapy.